Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Fabrizio Martora, Teresa Battista, Claudio Marasca, Lucia Genco, Gabriella Fabbrocini, Luca Potestio

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

Correspondence: Fabrizio Martora, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, Tel +39 - 081 - 7462457, Fax +39 - 081 - 7462442, Email fabriziomartora92@libero.it

Abstract: The outbreak of coronavirus disease 2019 (COVID-19) represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

Keywords: cutaneous reactions, COVID-19 vaccinations, side effects

Introduction

The outbreak of coronavirus disease 2019 (COVID-19) represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Dermatologists played a key role during the pandemic, fighting against several challenges such as cutaneous reactions caused by COVID-19 disease, the hesitancy on the efficacy and safety of conventional treatment and biologic drugs in this period, the worsening of several dermatosis due to the wearing of personal protection equipment and the introduction of a new lifestyle. Indeed, the “stay-at-home” policy and the restrictive measures adopted by the Italian Government during the COVID-19 pandemic period strongly affected the quality of life. In addition, COVID-19 restriction measures affect the epidemiology of infectious diseases and skin cancers.

Among the developed public health strategies to control the spread of COVID-19, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Fortunately, worldwide vaccination campaign was a success, showing to be the most effective weapon to prevent and control COVID-19 epidemic, disease progression, hospitalization and mortality.

According to the WHO COVID-19 dashboard accessed on 11 September 2021, more than 608 million confirmed cases of COVID-19 have been reported, with almost 6.51 million deaths. Nowadays, licensed vaccines for COVID-19, use nucleic acid-based vaccination platforms, such as viral vector platforms, messenger ribonucleic acid and inactivated virus.

Four vaccines have been approved by the European Medicines Agency (EMA): 2 mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273) and 2 viral-vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2.S). However, other vaccines have been approved in other countries such as...
“CoronaVac” (Sinovac), “Sputnik V” (Gamaleya Research Institute), and “Convidecia” (CanSino Biologics).\textsuperscript{13} Currently, more than 5.3 billion people have received at least one dose of COVID-19 vaccine.\textsuperscript{16}

Similar to other drugs, some people reported mild-to-moderate adverse events following vaccination, including fatigue, headache, diarrhea, redness or pain at the injection site, fever, muscle aches, chills.\textsuperscript{17–19} Fortunately, most of the side effects are limited, with a duration of few days.\textsuperscript{17–19}

Even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to recognize and treat them. In particular, a wide spectrum of cutaneous reactions has been reported.\textsuperscript{20} However, the significance of these reactions is still unknown. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations, which should be considered in personalized medicine.\textsuperscript{21,22}

Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

\section*{Materials and Methods}

For the current review, literature research was carried out on the PubMed, Embase, Cochrane Skin, Google Scholar, EBSCO and MEDLINE databases (until September 11, 2022). Research was performed by using the following keywords: “COVID-19”, “vaccination”, “vaccine”, “cutaneous”, “side effects”, “adverse events”, “skin manifestations”, “mRNA”, “viral-vector”, “Pfizer/BioNTech”, “BNT162b2”, “Moderna”, “mRNA-1273”, “AstraZeneca”, “AZD1222”, “Johnson & Johnson”, “Ad26.COV2.S”, “atopic dermatitis”, “psoriasis”, “lichen planus”, “bullous disease”, “pemphigus”, “pemphigoid”, “hidradenitis suppurativa”, “urticaria”, “rash”, “herpes”, “pityriasis rosea”, “chilblains”, “vitiligo”, “erythematous eruption”, “alopecia”, “local-injection”, “angioedema”, “eczema”. Analyzed articles included meta-analyses, reviews, letter to editor, real-life studies, case series and reports. The most relevant manuscripts were considered. Studies were selected if they provided information on cutaneous reactions following COVID-19 vaccination with BNT162b2, mRNA-1273, AZD1222 and Ad26.COV2.S, both first and second doses, if applicable. Cutaneous reactions following other vaccines, or the booster dose were excluded. Articles regarding skin reactions reported in clinical trials or with a limited number of cases were excluded. Manuscripts reporting local injection site reactions, both immediate and delayed, rash or unspecified cutaneous eruption and delayed inflammatory reactions to dermal hyaluronic acid filler were not considered. Moreover, articles where the vaccine leading to cutaneous reaction was not specified were excluded. Thus, the research was refined by reviewing the texts and the abstracts of collected articles. The bibliography was also reviewed to include articles that could have been missed. Only English language manuscripts were considered. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Details of the included studies are reported in Table 1.

\section*{Results}

A total of 1922 reports were initially found searching literature. Subsequently, 523 articles and 71 manuscripts were excluded since they were duplicates and in non-English languages, respectively. Then, literature review was refined following inclusion and exclusion criteria. Finally, a total of 183 articles involving 456 patients were selected in the current review. Main findings are summarized in Table 1.

Several cases of new onset or exacerbation of inflammatory skin diseases have been reported (Figure 1) as well as the type of vaccine causing these reactions has been investigated (Figure 2). As regards psoriasis, a total of 98 reports on psoriasis following COVID-19 vaccination were reported.\textsuperscript{23–54} In particular, flare of pre-existing disease and new-onset disease were reported in 81 and 17 cases, respectively. Moreover, several phenotypes of psoriasis were reported, with plaque subtype as the most frequent. Of note, even if biological treatments showed excellent results in terms of effectiveness and safety in psoriasis management,\textsuperscript{55–58} they seem to reduce the possibility of disease worsening following vaccination, without nullifying the risk. Moreover, the effectiveness of COVID-19 vaccines in patients undergoing treatment with biologics is debated.\textsuperscript{59,60}
Table 1 Main Cutaneous Reaction Following COVID-19 Vaccination

| Cutaneous Reaction               | Cases | Authors and Number of Cases                                                                 | Overall Reported Cases by Vaccines |
|----------------------------------|-------|---------------------------------------------------------------------------------------------|------------------------------------|
| New-onset psoriasis             | 17    | Tran et al\(^{23}\) (3), Ouni et al\(^{24}\) (2), Nagrani et al\(^{35}\) (1), Song et al\(^{46}\) (1), Frioui et al\(^{49}\) (1), Cortonesi et al\(^{50}\) (1), Lehmann et al\(^{51}\) (1), Elamin et al\(^{53}\) (1), Wei et al\(^{53}\) (1), Lamberti et al\(^{54}\) (1), Romagnuolo et al\(^{55}\) (1), Ruggiero et al\(^{56}\) (1), Ricardo et al\(^{57}\) (1), Pesqué et al\(^{58}\) (1). | BNT162b2: 10 mRNA-1273: 3 AZD1222: 3 Ad26.COV2: 1 |
| Flare of psoriasis              | 81    | Huang et al\(^{29}\) (15), Sotiriou et al\(^{30}\) (14), Koumaki et al\(^{31}\) (12), Megna et al\(^{32}\) (11), Wei et al\(^{33}\) (6), Ruggiero et al\(^{34}\) (4), Durmaz et al\(^{35}\) (2), Tran et al\(^{36}\) (2), Piccolo et al\(^{37}\) (2), Bostan et al\(^{38}\) (1), Nagrani et al\(^{39}\) (1), Pavia et al\(^{40}\) (1), Durmuss et al\(^{41}\) (1), Fang et al\(^{42}\) (1), Krajewski et al\(^{43}\) (1), Trepanowski et al\(^{44}\) (1), Miezczkowska et al\(^{45}\) (1), Lopez et al\(^{46}\) (1), Perna et al\(^{47}\) (1), Tsunoda et al\(^{48}\) (1), Nia et al\(^{49}\) (1), Pesqué et al\(^{50}\) (1). | BNT162b2: 43 mRNA-1273: 17 AZD1222: 21 Ad26.COV2: 0 |
| Cutaneous lichen planus          | 16    | New-onset: Merhy et al\(^{52}\) (1), Camela et al\(^{53}\) (1), Kato et al\(^{54}\) (1), Diab et al\(^{55}\) (1), Zagaria et al\(^{56}\) (1), Awada et al\(^{57}\) (1), Picone et al\(^{58}\) (1), Hlicit et al\(^{59}\) (1), Zengarini et al\(^{60}\) (1), Masseran et al\(^{61}\) (1), Gomonal et al\(^{62}\) (1), Alrawashdeh et al\(^{63}\) (1), Shakoei et al\(^{64}\) (1). Flare: Hiltun et al\(^{65}\) (1), Herzum et al\(^{66}\) (1), Hlicit et al\(^{67}\) (1). | BNT162b2: 8 mRNA-1273: 1 AZD1222: 7 Ad26.COV2: 0 |
| New-onset atopic dermatitis/eczema | 7     | Rerknimitr et al\(^{77}\) (3), Holmes et al\(^{78}\) (1), Leasure et al\(^{79}\) (1), Bekkali et al\(^{80}\) (1), Larson et al\(^{81}\) (1). | BNT162b2: 3 mRNA-1273: 1 AZD1222: 3 Ad26.COV2: 0 |
| Flare of atopic dermatitis/eczema | 14    | Potestio et al\(^{82}\) (11), Leasure et al\(^{83}\) (1), Niebel et al\(^{84}\) (1), Larson et al\(^{85}\) (1). | BNT162b2: 8 mRNA-1273: 3 AZD1222: 3 Ad26.COV2: 0 |
| Hidradenitis suppurativa         | 6     | Martora et al\(^{80}\) (5), Alexander et al\(^{89}\) (1). | BNT162b2: 2 mRNA-1273: 3 AZD1222: 1 Ad26.COV2: 0 |
| Urticaria                        | 98    | Magen et al\(^{84}\) (39), Potestio et al\(^{85}\) (15), Rerknimitr et al\(^{77}\) (12), Riad et al\(^{86}\) (10), Sidlow et al\(^{87}\) (3), Peigotto et al\(^{88}\) (2), Niebel et al\(^{89}\) (2), McMahon et al\(^{90}\) (2), Holmes et al\(^{78}\) (2), Fernandez-Nieto et al\(^{100}\) (2), Gianelli et al\(^{101}\) (2), Corbeddu et al\(^{102}\) (2), Baraldi et al\(^{103}\) (1), Choi et al\(^{104}\) (1), Patruno et al\(^{105}\) (2), Burlando et al\(^{106}\) (1), Thomas et al\(^{107}\) (1). | BNT162b2: 71 mRNA-1273: 12 AZD1222: 15 Ad26.COV2: 0 |
| Alopecia areata                  | 24    | Scollan et al\(^{109}\) (9), Babadjouni et al\(^{110}\) (3), Rossi et al\(^{111}\) (3), Chen et al\(^{112}\) (2), Abdalla et al\(^{113}\) (1), Gomonal et al\(^{114}\) (1), Ho et al\(^{115}\) (1), Su et al\(^{116}\) (1), Gallo et al\(^{117}\) (1), May Lee et al\(^{118}\) (1), Essam et al\(^{119}\) (1). | BNT162b2: 14 mRNA-1273: 4 AZD1222: 6 Ad26.COV2: 0 |
| Pemphigus vulgaris               | 26    | Martora et al\(^{121}\) (7), Zou et al\(^{122}\) (3), Giu et al\(^{123}\) (2), Rouatbi et al\(^{124}\) (2), Aryanian et al\(^{125}\) (1), Koutsas et al\(^{126}\) (1), Khechadi et al\(^{127}\) (1), Ong et al\(^{128}\) (1), Yildirici et al\(^{129}\) (1), Pehlivan et al\(^{130}\) (1), Norimatsu et al\(^{131}\) (1), Agharbi et al\(^{132}\) (1), Almasi-Nasrabadi et al\(^{133}\) (1), Corrá et al\(^{134}\) (1), Solimani et al\(^{135}\) (1). | BNT162b2: 15 mRNA-1273: 6 AZD1222: 5 Ad26.COV2: 0 |
| Pemphigoids                      | 40    | Maronese et al\(^{137}\) (21), Maronese et al\(^{138}\) (3), Hali et al\(^{139}\) (3), Gambichler et al\(^{140}\) (2), Shanshal et al\(^{141}\) (1), Desai et al\(^{142}\) (1), Fu et al\(^{143}\) (1), Alshammari et al\(^{144}\) (1), Hung et al\(^{145}\) (1), Paluzzi et al\(^{146}\) (1), Dell’Antonia et al\(^{147}\) (1), Pérez-López et al\(^{148}\) (1), Agharbi et al\(^{149}\) (1), Young et al\(^{150}\) (1), Nakamura et al\(^{151}\) (1). | BNT162b2: 29 mRNA-1273: 5 AZD1222: 6 Ad26.COV2: 0 |

(Continued)
Table 1 (Continued).

| Cutaneous Reaction | Cases | Authors and Number of Cases | Overall Reported Cases by Vaccines |
|--------------------|-------|-------------------------------|-----------------------------------|
| Morphea             | 9     | Paolino et al152 (4), Antoñanzas et al153 (2), Oh et al154 (1), Metin et al155 (1), Aryanian et al156 (1). | BNT162b2: 6 mRNA-1273: 6 AZD1222: 2 Ad26.COV2: 0 |
| Pityriasis rosea    | 40    | Temiz et al158 (14), Ramot et al159 (6), Martora et al160 (3), Khattab et al161 (2), Cyrenne et al162 (2), Valk et al163 (1), Buckley et al164 (1), Wang et al165 (1), Shin et al166 (1), Bostan et al167 (1), Leeraunyskul et al168 (1), Cohen et al169 (1), Dormann et al170 (1), Bin Rubaian et al171 (1), Fenner et al172 (1), Marcantoni-Santa Cruz et al173 (1), Abdullah et al174 (1), Carballido et al175 (1). | BNT162b2:33 mRNA-1273: 4 AZD1222: 2 Ad26.COV2: 1 |
| Herpes zoster       | 55    | Naoum et al178 (22), Agrawal et al179 (12), Monastirli et al180 (7), Furer et al181 (6), Vastarella et al182 (3), Palanivel et al183 (2), Vallianou et al184 (1), Jiang et al185 (1), You et al186 (1), Tanizaki et al187 (1). | BNT162b2:31 mRNA-1273: 5 AZD1222: 19 Ad26.COV2: 0 |
| Chilblains-like/pernio | 12   | Russo et al188 (3), Paparella et al189 (1), Davido et al190 (1), Lopez et al191 (1), Pilieri et al192 (1), Piccolo et al193 (1), Pérez-López et al194 (1), Cameli et al195 (1), Kha et al196 (1), Lesort et al197 (1). | BNT162b2:9 mRNA-1273: 2 AZD1222: 1 Ad26.COV2: 0 |
| Vitiligo            | 11    | Kaminetsky et al198 (1), Militello et al199 (1), Singh et al200 (1), Nicolaidou et al201 (1), Flores-Terry et al202 (1), Bukhari et al203 (1), Ujurer et al204 (1), Ciccarese et al205 (1), López Riquelme et al206 (1), Okan et al207 (1), Caroppo et al208 (1). | BNT162b2: 7 mRNA-1273: 3 AZD1222: 1 Ad26.COV2: 0 |

Abbreviations: BNT162b2, Pfizer mRNA; mRNA-1273, Moderna mRNA; AZD1222, Astrazeneca-Oxford AZD1222; Ad26.COV2, Johnson & Johnson Ad26.COV2.S.

Lichen planus is a chronic, inflammatory, autoimmune disease with an unknown pathogenesis.61 To date, 13 cases of new-onset cutaneous lichen planus and 3 cases of cutaneous lichen planus exacerbation have been reported.62–76 Like psoriasis, also cases of new onset and flare of atopic dermatitis or eczema have been reported (7 and 14, respectively).77–83 However, there is not a clear correlation with clinical phenotypes.84 Moreover, undergoing treatment with dupilumab does not seem to prevent the possibility of a flare of the disease, even if its efficacy and safety have been largely demonstrated.85,86 No data of atopic dermatitis worsening in patients undergoing treatment with Janus kinase inhibitors are available.87,88 Concerning hidradenitis suppurativa, there are currently few cases of new-onset disease (n = 1)99 or disease exacerbation (n = 5).90 However, patients with hidradenitis suppurativa are not at higher risk for any COVID-19 vaccine-related adverse outcomes.91,92

Urticarial rashes are the second most common cutaneous reaction following COVID-19 vaccination reported, following local injection site reactions, such as “Covid-arm”.93 Globally, 98 cases of urticarial eruptions following COVID-19 vaccination have been collected in our review,77,78,83,94–107 also during treatment with omalizumab.108

Alopecia areata has been reported following COVID-19 vaccination.109–119 The largest study on 77 patients developing alopecia areata (39) or a worsening of the disease (38) has been reported by Nguyen et al. Unfortunately, it is not possible to correlate alopecia areata development and the type of vaccine.120

Regarding bullous disorders, a total of 26 cases of pemphigus vulgaris have been reported following COVID-19 vaccination,121–135 with several implications in treatment and management.136 Moreover, 40 cases of pemphigoids have been described.137–151

Regarding other cutaneous diseases developed following COVID-19 vaccination, 9, 40, 55, 12 and 11 cases of morphea,152–157 pityriasis rosea,158–177 herpes zoster,178–187 chilblains,188–197 and vitiligo198–208 have been reported.
Figure 1: Cutaneous reactions investigated and number of cases.

Note: the different number of administered vaccines may explain the difference between the number of skin reactions following mRNA or viral vector-based vaccines.

Figure 2: Percentage of vaccine types investigated that cause cutaneous reactions.

Abbreviations: BNT162b2, Pfizer mRNA; mRNA-1273, Moderna mRNA; AZD1222, AstraZeneca-Oxford; Ad26.COV2, Johnson & Johnson Ad26.COV2.S.
Finally, several other dermatoses have been described, even if data are limited. Among these, we want to highlight pityriasis rubra pilaris, leukocytoclastic vasculitis, morbilliform rash, livedo racemosa, fixed drug eruption, erythema annulare centrifugum, granuloma annulare, fascial neutrophilic eruption, annular rash, Henoch-Schönlein purpura, dermatomyositis, regression of viral wart, raynaud phenomenon, eruptive angiomatosis, lichen striatus, pityriasis lichenoides et varioliformis acuta, Rowell’s syndrome, acrocyanosis, … suggesting that a wide type of dermatoses may be triggered by COVID-19 vaccination. However, most of these are limited to 1 or 2 case reports.

Discussion
COVID-19 pandemic revolutionized daily clinical practice. Indeed, several strategies were adopted to contain the spreading of the infection. Dermatologists had to change their clinical routine in order to avoid the reduction in detection and treatment of several conditions, particularly skin cancer. Among these, teledermatology allowed physicians to continuously assist patients’ dermatologic conditions with excellent results in terms of treatment adherence and clinical outcomes. Vaccination campaign is the most important strategy showing excellent results in terms of safety and effectiveness. Indeed, it allowed to reduce the severity and the impact of COVID-19 pandemic. However, several skin diseases induced or exacerbated by COVID-19 vaccination have been reported. Fortunately, most of them were mild and self-limited, not requiring medical attention. In our review, we highlighted several cutaneous reactions following COVID-19 vaccination such as psoriasis, atopic dermatitis, bullous disease, etc. Even if not specifically investigated, local injection-site reaction was the commonest cutaneous vaccine-related adverse event reported. Of note, cutaneous reactions were reported following vaccination with both mRNA and viral vector-based vaccines, suggesting that the pathogenetic mechanism underlying the cutaneous reaction is not directly related to the vaccine mechanism of action itself. Certainly, further studies are needed to understand pathogenetic mechanisms linking cutaneous reaction and COVID-19 vaccination in order to identify “at-risk” subjects and to adopt preventive measures.

Of note, among the articles reviewed in our work, the diagnosis of cutaneous reactions was confirmed by histopathological examination in most of the cases. However, a shared immune process was not found assessing the histological reports.

Overall, mRNA vaccines, particularly BNT162b2, seem to be most commonly associated with cutaneous reactions. However, mRNA vaccines were previously authorized, produced and administered worldwide. Thus, the different number of administered vaccines may explain the difference between the number of skin reactions following mRNA or viral vector-based vaccines. Further epidemiological studies will clarify if the percentage of cutaneous reactions following vaccination is significantly higher in one of the two types of vaccines, with clinical implications.

To sum up, our review analyzed several dermatoses exacerbated or developed following COVID-19 vaccination. However, the temporal association between the administration of the vaccine and the development of skin reaction may be casual.

As regards the dose of vaccination, cutaneous reactions were reported following both the first and the second dose of vaccine. Furthermore, skin reactions following both the doses in the same patient have been reported as well. In our opinion, clinicians should be prepared also to cutaneous reaction following the booster dose.

Strengths and Limitations
Main strengths of our review are the systematic method during the literature research and the high number of analyzed article and cutaneous reactions analyzed. Main limitations should be discussed. First, only the four vaccines approved by EMA have been considered. Moreover, several articles reporting registry-based studies did not allow the direct correlation between type of vaccine and cutaneous reaction. Finally, dermatological conditions developed following COVID-19 vaccination are usually mild and patients do not seek for medical attention.

Conclusion
With the worldwide advance of vaccination programs, several cutaneous reactions have been reported. Fortunately, the percentage of these adverse events is extremely low if compared with the number of vaccines administered. In our opinion, other cutaneous reactions following COVID-19 vaccination will be reported. Moreover, the pathogenetic mechanisms linking vaccination and skin reactions should be clarified. Clinicians should keep in mind the possibility...
of the exacerbation of the new onset of several dermatoses following vaccination in order to promptly recognize and differentiate vaccine-induced cutaneous manifestations from other clinical entities. Certainly, vaccination should not be discouraged.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**

1. Shivalkar S, Pingali MS, Verma A, et al. Outbreak of COVID-19: a detailed overview and its consequences. *Adv Exp Med Biol.* 2021;1353:23–45.
2. Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. *J Clin Med.* 2022;11(6):1511. doi:10.3390/jcm11061511
3. Ibrahim AE, Magdy M, Khalaf EM, et al. Telemedicine in the time of COVID-19. *Int J Clin Pract.* 2021;75(12):e15000. doi:10.1111/ijep.15000
4. Villani A, Fabbrocini G, Annunziata MC, et al. Maskne prevalence and risk factors during the COVID –19 pandemic. *J Eur Acad Dermatol Venereol.* 2022;36(9):e678–e680. doi:10.1111/jdv.18248
5. Ruggiero A, Martora F, Fornaro L, et al. The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre [published online ahead of print; 2022 Jun 21]. *Clin Exp Dermatol.* 2022. doi:10.1111/ced.15307
6. Martora F, Marasca C, Fabbrocini G, et al. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. *Clin Exp Dermatol.* 2022;47(10):1864–1865. doi:10.1111/ced.15291
7. Tull MT, Edmonds KA, Scamaldo KM, et al. Psychological outcomes associated with stay-at-home orders and the perceived impact of COVID-19 on daily life. *Psychiatry Res.* 2020;289:113098. doi:10.1016/j.psychres.2020.113098
8. Villani A, Scalfvenzi M, Fabbrocini G, et al. Effects of COVID-19 pandemic on malignant melanoma diagnosis. *J Eur Acad Dermatol Venereol.* 2022. doi:10.1111/jdv.18545
9. Picone V, Gallo L, Fabbrocini G, et al. Impact of COVID-19 pandemic and the use of telemedicine on the diagnosis and treatment of tinea corporis: an experience of Southern Italy center. *Dermatol Ther.* 2022; e15789. doi:10.1111/dth.15789
10. De Lucia M, Potestio L, Costanzo L, et al. Scabies outbreak during COVID-19: an Italian experience. *Int J Dermatol.* 2021;60(10):1307–1308. doi:10.1111/ijd.15809
11. Hudson A, Montelpare WJ. Predictors of vaccine hesitancy: implications for COVID-19 public health messaging. *Int J Environ Res Public Health.* 2021;18(15):8054. doi:10.3390/ijerph18158054
12. Olsanya OA, Bednarczyk RA, Davis RL, et al. Addressing parental vaccine hesitancy and other barriers to childhood/adolescent vaccination uptake during the coronavirus (COVID-19) pandemic. *Front Immunol.* 2021;12:663074. doi:10.3389/fimmu.2021.663074
13. Sharif N, Alzahrani KJ, Ahmed SN, et al. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. *Front Immunol.* 2021;12:714170. doi:10.3389/fimmu.2021.714170
14. COVID-19 dashboard by the Center For Systems Science And Engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html. Accessed September 22, 2022.
15. European Medicines Agency. COVID-19 vaccines: authorised. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/vaccines-authorised. Accessed November 2, 2022.
16. COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed September 11, 2022.
17. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. *JAMA.* 2021;326(14):1390–1399. doi:10.1001/jama.2021.15072
18. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (pfizer-biontech and moderna): update from the advisory committee on immunization practices - United States, July 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(32):1094–1099. doi:10.15585/mmwr.mrn7032e4
19. Walsh EE, French RWJ, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. *MMWR Morb Mortal Wkly Rep.* 2021;70(31):1006–1013. doi:10.15585/mmwr.mrn7031e2
20. Alzahrani KJ, Ahmed SN, et al. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. *Front Immunol.* 2021;12:714170. doi:10.3389/fimmu.2021.714170
21. COVID-19 dashboard by the Center For Systems Science And Engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html. Accessed September 22, 2022.
22. European Medicines Agency. COVID-19 vaccines: authorised. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/vaccines-authorised. Accessed November 2, 2022.
23. COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed September 11, 2022.
24. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. *JAMA.* 2021;326(14):1390–1399. doi:10.1001/jama.2021.15072
25. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (pfizer-biontech and moderna): update from the advisory committee on immunization practices - United States, July 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(32):1094–1099. doi:10.15585/mmwr.mrn7032e4
26. Walsh EE, French RWJ, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. *MMWR Morb Mortal Wkly Rep.* 2021;70(31):1006–1013. doi:10.15585/mmwr.mrn7031e2
27. Alzahrani KJ, Ahmed SN, et al. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. *Front Immunol.* 2021;12:714170. doi:10.3389/fimmu.2021.714170
28. COVID-19 dashboard by the Center For Systems Science And Engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html. Accessed September 22, 2022.
29. European Medicines Agency. COVID-19 vaccines: authorised. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/vaccines-authorised. Accessed November 2, 2022.
30. COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed September 11, 2022.
27. Ricardo JW, Lipner SR. Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. *JAAD Case Rep.* 2021;17:18–20. doi:10.1016/j.jder.2021.09.009

28. Pesqué D, Lopez-Trujillo E, Marcantionio O, et al. New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin? *J Eur Acad Dermatol Venereol.* 2021;35(12):e857–e859. doi:10.1111/jdv.17582

29. Huang Y-W, Tsai T-F. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. *Front Med.* 2021;8:812010. doi:10.3389/fmed.2021.812010

30. Sotiriou E, Tsentrimeidou A, Bakirtzi K, et al. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. *J Eur Acad Dermatol Venereol.* 2021;35(12):e857–e859. doi:10.1111/jdv.17582

31. Kounaki D, Krueger-Krasagakis S-E, Papadalakis M, et al. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre. *J Eur Acad Dermatol Venereol.* 2022;36:e411–e415. doi:10.1111/jdv.17965

32. Megna M, Potestio L, Gallo L, et al. Reply to “Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al. *J Eur Acad Dermatol Venereol.* 2022;36(e11–e13). doi:10.1111/jdv.17665

33. Durmaiz I, Turkmen D, Altunisik N, et al. Exacerbations of generalized pustular psoriasis, palmo-plantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: a report of three cases. *Dermatol Ther.* 2022;35(e15331). doi:10.1111/dth.15331

34. Tran TB, Pham NTU, Phan HN, et al. Generalized erythrodermic psoriasis triggered by vaccination against severe acute respiratory syndrome coronavirus 2. *Dermatol Ther.* 2022;35(e15464). doi:10.1111/dth.15464

35. Nagrani P, Jindal R, Goyal D. Onset / flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca / Covishield): report of two cases. *Dermatol Ther.* 2022;34(5):1–2. doi:10.1111/dth.15085

36. Piccolo V, Russo T, Mazzantena C, et al. COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. *J Eur Acad Dermatol Venereol.* 2022;36:e330–e332. doi:10.1111/jdv.17918

37. Bostan E, Elmars L, Yelcî-Yalici-Armagan B. Exacerbation of psoriasis following inactivated and BNT162b2 mRNA COVID-19 vaccines: a report of two cases. *Dermatol Ther.* 2021;34(6):1–3. doi:10.1111/dth.15110

38. Pavia G, Gargiulo S, Spinelli F, et al. Generalized pustulotic psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. *J Eur Acad Dermatol Venereol.* 2022;36:e502–e505. doi:10.1111/jdv.18032

39. Bulur D, Alkaya K, Karadag O, et al. Exacerbation of plaque psoriasis after vaccine with the Pfizer-BioNTech mRNA COVID-19 vaccine: a report of a single case. *J Eur Acad Dermatol Venereol.* 2022;35(e15363). doi:10.1111/dth.15363

40. Fang W-C, Chiu L-W, Hu -SC-S. Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine. *J Dermatol.* 2021;48:e566–e567. doi:10.1111/ced.14895

41. Krajewski PK, Matusiak Ł, Szepietowski JC. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT162B2 COVID-19 mRNA vaccine. *J Dermatol.* 2021;48:e566–e567. doi:10.1111/ced.15395

42. Huang Y-W, Tsai T-F. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. *Front Med.* 2021;8:812010. doi:10.3389/fmed.2021.812010

43. Mieczkowska K, Kaubisch A, McLellan BN. Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor. *Dermatol Ther.* 2021;34(5):10–11. doi:10.1111/dth.15055

44. Lopez ED, Javed N, Upadhyay S, et al. Acute exacerbation of psoriasis after COVID-19 Pfizer vaccine. Proceedings (Baylor University. Medical Center); 2022: 199–201.

45. Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. *JAAD Case Rep.* 2021;17:1–3. doi:10.1016/j.jder.2021.08.035

46. Song WJ, Lim Y, Jo SJ. De novo guttate psoriasis following coronavirus disease 2019 vaccine. *J Dermatol.* 2022;49:e30–e31. doi:10.1111/1346-8138.16203

47. Tsunoda K, Watabe D, Amano H. Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BNT162B2 mRNA COVID-19 vaccine during risankizumab treatment. *J Dermatol.* 2022. doi:10.1111/1346-8138.16505

48. Nia AM, Silva MM, Spauve J, et al. Erythrodermic psoriasis eruption associated with SARS-CoV-2 vaccination. *Dermatol Ther.* 2022;35:e15444. doi:10.1111/dth.15444

49. Frioni R, Chamli A, Zaouak A, et al. A case of new-onset acute generalized pustular psoriasis following Pfizer-BioNTech COVID-19 vaccine. *Dermatol Ther.* 2022;35:e15444. doi:10.1111/dth.15444

50. Cortonesi G, Orcini C, Rubergi P, et al. New-onset psoriasis after Comirnaty (BNT162b2, BioNTech /Pfizer) vaccine successfully treated with ixekizumab. *Dermatol Ther.* 2022;35:e15606. doi:10.1111/dth.15606

51. Lehmann M, Schorno P, Hunger RE, et al. New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. *J Eur Acad Dermatol Venereol.* 2021;35(11):e752–e755. doi:10.1111/jdv.17561

52. Elamin S, Hinds F, Tolland J. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. *Clin Exp Dermatol.* 2022;47:153–155. doi:10.1111/ced.14895

53. Wei N, Kresech M, Elbogen E, et al. New onset and exacerbation of psoriasis after COVID-19 vaccination. *JAAD Case Rep.* 2022;19:74–77. doi:10.1016/j.jder.2021.11.016

54. Lamberti A, Lora V, Gracceffà D, et al. Nail psoriasis: a rare mRNA COVID–19 vaccine reaction. *J Eur Acad Dermatol Venereol.* 2022;36(10). doi:10.1111/jdv.18255

55. Ruggiero A, Picone V, Martora F, et al. Guttate psoriasis triggered by the Pfizer-BioNTech mRNA COVID-19 vaccine: a new therapeutic option for guttate psoriasis? *Clin Cosmet Investig Dermatol.* 2022;15:1649–1658. doi:10.2147/CCID.S364640

56. Megna M, Potestio L, Fabbroni G, et al. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? *Dermatol Ther.* 2021;34(5):e1530. doi:10.1111/dth.15300

57. Megna M, Potestio L, Fabbroni G, et al. Treating psoriasis in the elderly: biologics and small molecules. *Expert Opin Biol Ther.* 2022;1–18. doi:10.1080/14712598.2022.2089020

58. Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. *Dermatol Ther.* 2022;35:e15524. doi:10.1111/dth.15524

59. Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. *Clin Exp Dermatol.* 2022. doi:10.1111/ced.15395
60. Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. *Clin Exp Dermatol*. 2022. doi:10.1111/ced.15336

61. Usatine RP, Tintignac M. Diagnosis and treatment of lichen planus. *Am Fam Physician*. 2011;84(1):53–60.

62. Merhy R, Sarkis A-S, Kaikati J, et al. New-onset cutaneous lichen planus triggered by COVID-19 vaccination. *J Eur Acad Dermatol Venereol*. 2021;35(11):e729–e730. doi:10.1111/jdv.17504

63. Camela E, Guerrasio G, Patruncio C, et al. Reply to “New-onset cutaneous lichen planus triggered by COVID-19 vaccination” by Merhy et al. *J Eur Acad Dermatol Venereol*. 2022;36:e249–e251. doi:10.1111/jdv.17866

64. Gamonal SBL, Gamonal ACC, Marques NCV, et al. Lichen planus flare following COVID-19 vaccination. *Dermatol Ther*. 2022;35(5):e15422.

65. Alrawashdeh HM, Al-Habahbeh O, Naser AY, et al. Lichen planus eruption following oxford-AstraZeneca COVID-19 vaccine administration: a case report and review of literature. *Cureus*. 2022;14:e22669. doi:10.7759/cureus.22669

66. Shakoei S, Kalantari Y, Nasimi M, et al. Cutaneous manifestations following COVID-19 vaccination: a report of 25 cases. *Dermatol Ther*. 2022;35(8):e15651. doi:10.1111/dth.15651

67. Hiltun I, Sarriugarte J, Martínez-de-Espronceda I, et al. Lichen planus arising after COVID-19 vaccination. *Dermatol Ther*. 2021;34(11):e15389. doi:10.1111/ced.15389

68. Herzum A, Burlando M, Molle MF, et al. Lichen planus flare following COVID-19 vaccination: a case report. *Clin Case Rep*. 2021;9(12):e05092. doi:10.1002/ccr3.5092

69. Kato J, Kamiya T, Handa T, et al. Linear lichen planus after COVID-19 vaccination. *Australas J Dermatol*. doi:10.1111/ajd.13902

70. Diab R, Araghi F, Gheisari M, et al. Lichen planus and lichen planopilaris flare after COVID –19 vaccination. *Dermatol Ther*. 2022;35(3):e15283. doi:10.1111/dth.15283

71. Zagaria O, Villani A, Ruggiero A, et al. New-onset lichen planus resulting from local cervical lymph node swelling after COVID-19 vaccination. *Dermatol Ther*. 2022;35(5):e15374. doi:10.1111/dth.15374

72. Awada B, Abdallah L, Kurban M, et al. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine. *J Cosmet Dermatol*. 2022;21(3):883–885. doi:10.1111/jocd.14738

73. Picone V, Fabbrocini G, Martora F, et al. A case of new-onset lichen planus flare following COVID-19 vaccination. *Dermatol Ther*. 2022;12(3):801–805. doi:10.1111/j.1555-0222-00689-y

74. Hlaca N, Zagar T, Kastelan M, et al. New-onset lichen planus and lichen planus flare in elderly women after COVID-19 vaccination. *J Cosmet Dermatol*. 2022;21(9):3679–3681. doi:10.1111/jocd.15185

75. Zengarini C, Piraccini BM, La Placa M. Lichen Ruber Planus occurring after SARS-CoV-2 vaccination. *Dermatol Ther*. 2022;35:15389. doi:10.1111/ced.15389

76. Masseran C, Calugareanu A, Caux F, et al. Extensive cutaneous lichen planus triggered by viral vector COVID-19 vaccination (ChAdOx1 nCoV-19). *J Eur Acad Dermatol Venereol*. 2022;36(4):e263–5. doi:10.1111/jdv.17899

77. Rerknimitr P, Puarananaarunkon T, Wongtada C, et al. Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers. *J Eur Acad Dermatol Venereol*. 2022;36:e158–61. doi:10.1111/jdv.17761

78. Holmes GA, Desai M, Limone B, et al. A case of cutaneous COVID-19 vaccine reactions at Loma Linda university department of dermatology. *JAAD Case Rep*. 2021;16:53–57. doi:10.1016/j.jdercrep.2021.07.038

79. Leasure AC, Cowper SE, McNiff J, et al. Generalized eczematoid reactions to the Pfizer-BioNTech COVID-19 vaccine. *J Eur Acad Dermatol Venereol*. 2021;35(11):e716–e717. doi:10.1111/jdv.17494

80. Bekkali N, Allard T, Lengellé C, et al. Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID −19 vaccination in patients with hidradenitis suppurativa’. *J Dermatolog Ther*. 2021;34(6):e15120. doi:10.1111/dth.15120

81. Larson V, Seidenberg R, Caplan A, et al. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID –19 vaccination. *J Cutan Pathol*. 2021;49(1):34–41. doi:10.1111/jcp.14104

82. Potestio L, Napolitano M, Bennardo L, et al. Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. *J Eur Acad Dermatol Venereol*. 2022;36(6):e409–411. doi:10.1111/jdv.17964

83. Niebel D, Wenzel J, Wilsmann-Theis D, et al. Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccination. *Dermatopathology*. 2021;84(1):53–60. doi:10.1080/09546634.2022.2080840

84. Patruncio C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. *Curr Opin Allergy Clin Immunol*. 2022;25:13–14. doi:10.1097/ACI.0000000000000837

85. Patruncio C, Potestio L, Scalevenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. *J Dermatolog Treat*. 2022;3–6. doi:10.1080/09546634.2022.2102121

86. Napolitano M, Maffei M, Patruncio C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. *Dermatol Ther*. 2021;34(6):e15120. doi:10.1111/dth.15120

87. Patruncio C, Potestio L, Napolitano M, Fabbrocini G, Genco L, et al. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. *J Eur Acad Dermatol Venereol*. 2022;36(9):1497–1498. doi:10.1111/jdv.18137

88. Cantelli M, Martora F, Patruncio C, et al. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. *Dermatol Ther*. 2022;35(5):e15346. doi:10.1111/dth.15346

89. Alexander H, Patel NP. Response to Martora et al’s “Hidradenitis suppurativa flares following COVID-19 vaccination: a case series”. *JAAD Case Rep*. 2022;25:13–14. doi:10.1016/j.jdercrep.2022.05.005

90. Martora F, Picone V, Fabbrocini G, et al. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. *JAAD Case Rep*. 2022;23:42–45. doi:10.1016/j.jdercrep.2022.03.008

91. Pakchhanian H, Raiker R, DeYoung C, et al. Evaluating the safety and efficacy of COVID −19 vaccination in patients with hidradenitis suppurativa. *Clin Exp Dermatol*. 2022;47:1186–1188. doi:10.1111/ced.15090

92. Martora F, Marasca C, Battista T, et al. Management of patients with hidradenitis suppurativa during COVID −19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID −19 vaccination in patients with hidradenitis suppurativa’. *Clin Exp Dermatol*. 2022;47(11):2026–2028. doi:10.1111/ced.15306
93. Picone V, Martora F, Fabbrocini G, et al. “Covid arm”: abnormal side effect after Moderna COVID –19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
94. Magen E, Yakov A, Green I, et al. Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy Asthma Pers Med. 2022;43(1):30–36. doi:10.2500/aap.2022.43.210111
95. Potestio L, Genco L, Villani A, et al. Reply to “Cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study”. by Bawane J et al. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18341
96. Riad A, Pokorná A, Atta S, et al. Prevalence of COVID–19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428. doi:10.3390/jm10071428
97. Sidlow JS, Reichel M, Lowenstein EJ. Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients. JAAD Case Rep. 2021;14:13–16. doi:10.1016/j.jder.2021.05.018
98. Peigottu MF, Ferreli C, Atzori MG, et al. Skin adverse reactions to novel messenger RNA coronavirus vaccination: a case series. Disease. 2021;9(3):58. doi:10.3390/diseases9030058
99. McMahon DE, Ferreli C, Atzori MG, et al. Skin adverse reactions to novel messenger RNA coronavirus vaccination: a case series. Allergy. 2021;76(8):2605–2607. doi:10.1111/all.14839
100. McManus DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113–121. doi:10.1016/j.jaad.2021.09.002
101. Fernandez-Nieto D, Hammerle J, Fernandez-Escribano M, et al. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. “COVID Arm”: a clinical and histological characterization. J Eur Acad Dermatol Venereol. 2021;35:e425–e427. doi:10.1111/jdv.17250
102. Corbeddu M, Diociaiuti A, Vinci MR, et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series. J Eur Acad Dermatol Venereol. 2021;35:e483–e485. doi:10.1111/jdv.17268
103. Baraldi C, Boling LB, Patrizi A, et al. Unique case of urticarial skin eruptions after COVID-19 vaccination. Allergy. 2022;74:198–200. doi:10.1111/ada.15006
104. Choi E, Liew CF, Oon HH. Cutaneous adverse effects and contraindications to COVID-19 vaccination: four cases and an illustrative review from an Asian country. Dermatol Ther. 2021;34:e15123. doi:10.1111/dth.15123
105. Patruno C, Napolitano M, Stingeni L, et al. Skin rashes after SARS-CoV-2 vaccine: which relationship if any? Immunity Inflamm Dis. 2021; (3):622–623. doi:10.1002/idi.428
106. Burlando M, Herzum A, Cozzani E, et al. Acute urticarial rash after COVID-19 vaccination containing polysorbate 80. Clin Exp Vaccine Res. 2021;10(3):298–300. doi:10.7774/cevr.2021.10.3.298
107. Thomas J, Thomas G, Chatim A, et al. Chronic spontaneous urticaria after COVID-19 vaccine. Cureus. 2021;13(9):e18102.
108. Picone V, Napolitano M, Martora F, et al. Urticaria Relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: a single-center experience. Dermatol Ther. 2022. e15838. doi:10.1111/dth.15838
109. Scollan ME, Breneman A, Kirnariwalla N, et al. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:1–5. doi:10.1016/j.jder.2021.11.023
110. Babadjou A, Phong CH, Nguyen C, et al. COVID-19 vaccination related exacerbations of hair loss in patients with moderate to severe alopecia areata on systemic therapy. JAAD Case Rep. 2022;29:181–185. doi:10.1016/j.jcder.2022.08.016
111. Rossi A, Magri F, Michelini S, et al. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy. J Cosmet Dermatol. 2021;20(12):3753–3757. doi:10.1111/jocd.14581
112. Chen C-H, Chen Y-Y, Lan C-CE. Intractable alopecia areata following the second dose of COVID-19 vaccination: report of two cases. Dermatol Ther. 2022;35:e15689. doi:10.1111/dth.15689
113. Abdalla H, Ebrahim E. Alopecia areata universalis precipitated by SARS-CoV-2 vaccine: a case report and narrative review. Cureus. 2022;14:e2795. doi:10.7755/cureus.27953
114. Gamonal SBL, Marques NCV, Pereira HMB, et al. New-onset systemic lupus erythematosus after ChAdOx1 nCoV-19 and alopecia areata after BNT162b2 vaccination against SARS-CoV-2. J Cosmet Dermatol. 2022;35:e15677. doi:10.1111/dth.15677
115. Ho JD, McNish A, McDonald L, et al. Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222). JAAD Case Rep. 2022;25:4–8. doi:10.1016/j.jcder.2022.05.002
116. Su H-A, Juan C-K, Chen Y-C. Alopecia areata following ChAdOx1 nCoV-19 vaccination (Oxford/AstraZeneca). J Formosan Med Assoc. 2022;121(10):2138–2140. doi:10.1016/j.jfma.2022.03.006
117. Gallo G, Mastorino L, Tonella L, et al. Alopecia areata after COVID-19 vaccination. Clin Exp Vaccine Res. 2022;11(1):129–132. doi:10.7774/cevr.2021.11.1.129
118. May Lee M, Bertolani M, Pierobon E, et al. Alopecia areata following COVID –19 vaccination: vaccine-induced autoimmunity? Int J Dermatol. 2022;61:634–635. doi:10.1111/ijd.16113
119. Essam R, Ehab R, Al-Razzaz R, et al. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor? J Cosmet Dermatol. 2021;20:3727–3729. doi:10.1111/jocd.14459
120. Nguyen B, Tosti A. Alopecia areata after COVID-19 infection and vaccination: a cross-sectional analysis. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18491
121. Martora F, Fabbrocini G, Nappa P, et al. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV –2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750–e751. doi:10.1111/jdv.18302
122. Oumar F, Al-Razzaz R, Essam R, et al. Alopecia areata after COVID-19 vaccination. Dermatol Ther. 2022;35:e15827. doi:10.1111/dth.15827
123. Ayhan Z, Baligil K, Azizpour A, et al. Coexistence of pemphigus vulgaris and lichen planus following COVID-19 vaccination. Case Rep Dermat Med. 2022;2022:2324212. doi:10.1155/2022/2324212
126. Koutras IG, Camara R, Argyris PP, et al. Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine. Oral Dis. 2021. doi:10.1111/odi.14089
127. Knechtl GV, Seyed Jafari SM, Berger T, et al. Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient. J Eur Acad Dermatol Venereol. 2022;36(4):e251–e253. doi:10.1111/jdv.17868
128. Ong SK, Darji K, Chaudhry SB. Severe flare of pemphigus vulgaris after first dose of COVID-19 vaccine. JAAD Case Rep. 2022;22:50–52. doi:10.1016/j.jdercr.2022.01.027
129. Yildrnci Ş, Yılıh S, Demirkesen C, et al. New onset of pemphigus foliaceous following BNT162b2 vaccine. Dermatol Ther. 2022;35:e15381. doi:10.1111/dth.15381
130. Singh A, Bharadwaj SI, Chirayath AG, et al. Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature. J Cosmet Dermatol. 2022;21(6):2311–2314. doi:10.1111/jocd.14945
131. Norimatsu Y, Yoshizaki A, Yamada T, et al. Pemphigus vulgaris with advanced hypoperyngogal and gastric cancer following SARS-CoV-2 vaccination. J Dermatol. 2022. doi:10.1111/1346-8138.16539
132. Agharbi F-Z, Basri G, Chiheb S. Pemphigus vulgaris following second dose of mRNA-(Pfizer-BioNtech) COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2022;35(10):e15769. doi:10.1111/dth.15769
133. Almasi-Nasrabadi M, Ayayalaru RS, Sharma A, et al. New onset pemphigus foliaceous following AstraZeneca COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/dth.18484
134. Corrì A, Barei F, Genovese G, et al. Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019. J Dermatol. 2022. doi:10.1111/1346-8138.16554
135. Solimani F, Mansour D, Didona D, et al. Development of pemphigoid following SARS-CoV-2 vaccination with BNT162b2. J Eur Acad Dermatol Venereol. 2022;35(10):e649–51. doi:10.1111/jdv.17480
136. Martora F, Battista T, Nappa P, et al. Pemphigus vulgaris and COVID-19 vaccination: management and treatment. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15374
137. Maronese CA, Caproni M, Moltrasio C, et al. Bullous pemphigoid associated with COVID-19 vaccines: an Italian multicentre study. Front Med. 2022;9:841506. doi:10.3389/fmed.2022.841506
138. Maronese CA, Di Zenzo G, Genovese G, et al. Reply to “New-onset bullous pemphigoid after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin”. Dermatol Ther. 2022;35:e15496. doi:10.1111/dth.15496
139. Hali FS, Araqi LJ, Marnissi F, et al. Autoimmune bullous dermatosis following COVID-19 vaccination: a series of five cases. Cureus. 2022;14:e23127. doi:10.7759/cureus.23127
140. Gambichler T, Hamdani N, Budde H, et al. Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol. 2022;186(4):728–731. doi:10.1111/bjd.20890
141. Shanshal M. Dyshidrosiform bullous pemphigoid triggered by COVID-19 vaccination. Cureus. 2022;14:e26383. doi:10.7759/cureus.26383
142. Desai AD, Shah R, Haroon A, et al. Bullous pemphigoid following the moderna mRNA-1273 vaccine. Cureus. 2022;14:e24126. doi:10.7759/cureus.24126
143. Fu P-A, Chen C-W, Hsu Y-T, et al. A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination. J Formosan Med Assoc. 2022;121(9):1872–1876. doi:10.1016/j.jfma.2022.02.017
144. Alshammary F, Abuzied Y, Koraini A, et al. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: a case report. Ann Med Surg. 2022;75:103420. doi:10.1016/j.amsu.2022.103420
145. Hang W-K, Chi C-C. Incident bullous pemphigoid in a pioriatic patient following mRNA-1273 SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2022;36:e407–e409. doi:10.1111/jdv.17955
146. Pauluzzi M, Stincio G, Errichetti E. Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review. J Eur Acad Dermatol Venereol. 2022;36:e257–e259. doi:10.1111/jdv.17891
147. Dell’Antonia M, Aredda S, Usai F, et al. Bullous pemphigoid triggered by COVID-19 vaccine: rapid resolution with corticosteroid therapy. Dermatol Ther. 2022;35:e15208. doi:10.1111/dth.15208
148. Pérez-López I, Moyano-Bueno D, Ruiz-Villaverde R. Bullous pemphigoid and COVID-19 vaccine. Med Clin. 2021;157(10):e333–e334. doi:10.1016/j.medcli.2021.05.005
149. Agharbi F-Z, Eljazouly M, Basri G, et al. Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine. Ann Dermatol Venereol. 2022;149:56–57. doi:10.1111/and.2021.07.008
150. Young J, Merceica L, Ceci M, et al. A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine. J Eur Acad Dermatol Venereol. 2022;36(1):e13–e16. doi:10.1111/jdv.17676
151. Nakamura K, Kosano M, Sakai Y, et al. Case of bullous pemphigoid following coronavirus disease 2019 vaccination. J Dermatol. 2021;48(12):e606–e607. doi:10.1111/jdv.17676
152. Paolino G, Campochiaro C, Di Nicola MR, et al. Generalized morphea after COVID-19 vaccines: a case series. J Eur Acad Dermatol Venereol. 2022;36:e680–e682. doi:10.1111/jdv.18249
153. Antohanzas J, Rodríguez-Garrio N, Estenaga A, et al. Generalized morphea following the COVID vaccine: a series of two patients and a bibliographic review. Dermatol Ther. 2022;35(9):e15709. doi:10.1111/dth.15709
154. Oh DAQ, Heng YK, Tee S-I. Morpoea following COVID-19 Vaccination. Clin Exp Dermatol. 2022. doi:10.1111/ced.15349
155. Metin Z, Celepli P. A case of morphea following the COVID-19 mRNA vaccine: on the basis of viral spike proteins. Int J Dermatol. 2022;61:639–641. doi:10.1111/ijd.16062
156. Aryanian Z, Balighi K, Hatami P, et al. Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection. Clin Case Rep. 2022;10(4):e55667. doi:10.1002/ccr3.5667
157. Martora F, Battista T, Ruggiero A, et al. Reply to “Morphea following COVID-19 Vaccination”. Clin Exp Dermatol. 2022. doi:10.1111/ced.15396
158. Temiz SA, Abdelmaksoud A, Dursun R, et al. Pityriasis rosea following SARS-CoV-2 vaccination: a case series. J Cosmet Dermatol. 2021;20(10):3080–3084. doi:10.1111/jocd.14372
159. Ramot Y, Nanova K, Faitatzidou S-M, et al. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2. J der Deutschen Dermatologischen Gesellschaft. 2022;20:1123–1124.
Martora et al

1. Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. *Dermatol Ther.* 2022;35(2):e15225. doi:10.1111/dth.15225

2. Khattab E, Christaki E, Pitsios C. Pityriasis rosea induced by COVID-19 vaccination. *Eur J Case Rep Intern Med.* 2022;9(2):3164.

3. Cyrenne BM, Al-Mohammed F, DeKoven JG, et al. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. *J Eur Acad Dermatol Venereol.* 2021;35:e546–e548. doi:10.1111/jdv.17342

4. Valk B, Bender B. Pityriasis rosea associated with COVID-19 vaccination: a common rash following administration of a novel vaccine. *Curr Top Microbiol Immunol.* 2021;108(6):317–318. doi:10.1007/86-44-0141

5. Buckley JE, Landis LN, Rapini RP. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: a case report and review of the literature. *JAAD Int.* 2022;7:164–168. doi:10.1016/j.jdrip.2022.01.009

6. Wang C-S, Chen -H-H, Liu S-H. Pityriasis rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review. *J Formos Med Assoc.* 2022;121:1003–1007. doi:10.1016/j.jfma.2021.12.028

7. Shin SH, Hong JK, Hong SA, et al. Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination. *Int J Infect Dis.* 2022;114:88–89.

8. Bostan E, Jarbou A. Atypical pityriasis rosea associated with mRNA COVID-19 vaccine. *J Med Virol.* 2022;94:814–816. doi:10.1002/jmv.27364

9. Leernuyakul K, Pakornphadungsit K, Suchonwanit P. Case report: pityriasis rosea-like Eruption following COVID-19 vaccination. *Front Med.* 2021;8:752443. doi:10.3389/fmed.2021.752443

10. Cohen OG, Clark AK, Milbar H, et al. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. *Hum Vaccin Immunother.* 2021;17(11):4097–4098. doi:10.1080/26455152.2019.1663173

11. Dormann H, Grummt S, Karg M. Pityriasis rosea as a possible complication of vaccination against COVID-19. *Dtsch Arztebl Int.* 2021;118(25):431. doi:10.3238/arztebl.2021.0257

12. Bin Ruabaen NF, Almuhaidib SR, Aljarri SA, et al. Pityriasis rosea following pfizer-BioNTech vaccination in an adolescent girl. *Cureus.* 2022;14:e27108. doi:10.7759/cureus.27108

13. Fenner B, Marquez JL, Pham M, et al. Inverse pityriasis rosea secondary to COVID-19 vaccination. *Proceedings (Baylor University. Medical Center);* 2022;342–343.

14. Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesque D, et al. Pityriasis rosea developing after COVID-19 vaccination. *J Eur Acad Dermatol Venereol.* 2021;35:e721–e722. doi:10.1111/jdv.17498

15. Abdullah L, Hasbani D, Kurban M, et al. Pityriasis rosea after mRNA COVID-19 vaccination. *Int J Dermatol.* 2021;60(9):1150–1151. doi:10.1111/ijd.15700

16. Carballido Vázquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination. *Br J Dermatol.* 2021;185(2):e34. doi:10.1111/bjd.20143

17. Martora F, Picone V, Fornaro L, et al. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? *J Med Virol.* 2022;94(4):1292–1293. doi:10.1002/jmv.27535

18. Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions after COVID-19 vaccines. *JAAD Int.* 2022;9:127. doi:10.1016/j.jdid.2022.03.018

19. Naoun C, Hartmann M. Herpes zoster reactivation after COVID-19 vaccination - A retrospective case series of 22 patients. *Int J Dermatol.* 2022;61:628–629. doi:10.1111/ijd.161116

20. Agrawal S, Verma K, Verma I, et al. Reactivation of herpes zoster virus after COVID-19 vaccination: is there any association? *Cureus.* 2022;14(5):e25195. doi:10.7759/cureus.25195

21. Monastirli A, Pasmatzi E, Badavanis G, et al. Herpes Zoster after mRNA COVID-19 vaccination: a case series. *Skinmed.* 2022;20(4):284–288.

22. Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. *Rheumatology.* 2021;60(S1):S190–S195. doi:10.1093/rheumatology/keab345

23. Vastarella M, Picone V, Martora F, et al. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series. *J Eur Acad Dermatol Venereol.* 2021;35(12):e845–e846. doi:10.1111/jdv.17576

24. Palanivel JA. Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? *J Cosmet Dermatol.* 2021;20:3367–3377. doi:10.1111/jocd.14470

25. Vallianou NG, Tsilingiris D, Karampela I, et al. Reactivation of herpes zoster virus after COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: a two-vaccine related event? *Metab Open.* 2022;13:100171. doi:10.1016/j.metop.2022.100171

26. Jiang Z-H, Wong L-S, Lee C-H, et al. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination. *Indian J Dermatol Venereol Leprol.* 2022;88:445. doi:10.25259/IDVL_819_2021

27. You I-C, Ahn M, Cho N-C, Case A. Report of herpes zoster ophthalmicus and meningitis after COVID-19 vaccination. *J Korean Med Sci.* 2022;37:e165. doi:10.3346/jkms.2022.37.e165

28. Tanizaki R, Miyasato Y. Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient. *IDCases.* 2022;29:e01563. doi:10.1016/j.idcar.2022.e01563

29. Russo R, Cozzani E, Micalizzi C, et al. Chilblain-like lesions after COVID-19 vaccination: a case series. *Acta Derm Venereol.* 2022;102:adv0071. doi:10.2340/actadv.v102.2076

30. Paparella R, Tarani L, Properzi E, et al. Chilblain-like lesions onset during SARS-CoV-2 infection in a COVID-19-vaccinated adolescent: case report and review of literature. *Ital J Pediatr.* 2022;48(1):93. doi:10.1186/s13052-022-01296-5

31. Davido B, Mascetti H, Fortier-Beaulieu M, et al. “Blue toes” following vaccination with the BNT162b2 mRNA COVID-19 vaccine. *J Travel Med.* 2022;28(4): doi:10.1093/jtm/taab024

32. Lopez S, Vakharia P, Vandergriff T, et al. Pernio after COVID-19 vaccination. *Br J Dermatol.* 2021;185(2):445–447. doi:10.1111/bjd.20404

33. Pileri A, Galliglomo A, Raone B, et al. Chilblain lesions after COVID-19 mRNA vaccine. *Br J Dermatol.* 2021;185(1):e3. doi:10.1111/bjd.20600

34. Piccolo V, Bassi A, Argenziano G, et al. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. *J Eur Acad Dermatol Venereol.* 2021;35:e493–e494. doi:10.1111/jdv.17320

35. Pérez-López I, Gil-Villalba A, Ruiz-Villaverde R. Perniosis-like lesions after vaccination with mRNA against COVID-19. *Med Clin (Barc).* 2022;158:189–190. doi:10.1016/j.medcli.2021.05.016
195. Cameli N, Silvestri M, Mariano M, et al. Pemiglotys-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(11):c725–c727. doi:10.1111/jdv.17500
196. Kha C, Ikin A. New-onset chillblains in close temporal association to mRNA-1273 vaccination. JAAD Case Rep. 2021;12:12–14. doi:10.1016/j.jdcr.2021.03.046
197. Lesort C, Kanitakis J, Donzier L, et al. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that “COVID toes” are due to the immune reaction to SARS-CoV-2. J Eur Acad Dermatol Venereol. 2021;35:e630–2. doi:10.1111/jdv.17451
198. Kaminetsky J, Rudikoff D. New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination. Clin Case Rep. 2021;9:e04865. doi:10.1002/ccr3.4865
199. Mülțel M, Ambur AB, Steffes W. Vitiligo possibly triggered by COVID-19 vaccination. Cureus. 2022;14:e20902. doi:10.7759/cureus.20902
200. Singh R, Cohen JL, Astudillo M, et al. Vitiligo of the arm after mRNA COVID-19 vaccination. JAD Case Rep. 2022;28:142–144. doi:10.1016/j.jdcr.2022.06.003
201. Nicolaidou E, Vavouli C, Komprentziotsi I-A, et al. New-onset vitiligo after COVID−19 mRNA vaccination: a causal association? J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18513
202. Flores-Terry MÁ, García-Arpa M, Santiago-Sánchez Mateo JL, et al. Facial vitiligo after SARS-CoV-2 vaccination. Actas Dermosifiliogr. 2022;113(7):721. Spanish. doi:10.1016/j.ad.2022.01.030
203. Bukhari AE. New-onset vitiligo in a child following COVID-19 vaccination. JAAD Case Rep. 2022;22:68–69. doi:10.1016/j.jdcr.2022.02.021
204. Uğurer E, Sivaz O, Kıvanç Altunay İ, et al. Newly-developed vitiligo following COVID-19 mRNA vaccine. J Cosmet Dermatol. 2022;21(4):1350–1351. doi:10.1111/jocd.14843
205. Ciccagrose G, Drago F, Boldrin S, et al. Sudden onset of vitiligo after COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15196. doi:10.1111/dth.15196
206. López Riqueleme I, Fernández Ballestros MD, Serrano Ordoñez A, et al. COVID−19 and autoimmune phenomena: vitiligo after AstraZeneca vaccine. Dermatol Ther. 2022;35:e15502. doi:10.1111/dth.15502
207. Okan G, Vural P. Worsening of the vitiligo following the second dose of BNT162B2 mRNA COVID-19 vaccine. Dermatol Ther. 2022;35:e15280. doi:10.1111/dth.15280
208. Caroppo F, Deotto ML, Tartaglia J, et al. Vitiligo worsened following the second dose of mRNA SARS-CoV−2 vaccine. Dermatol Ther. 2022;35:e15434. doi:10.1111/dth.15434
209. Martora F, Villani A, Marasca C, et al. Skin reaction after SARS-CoV−2 vaccines Reply to ‘cutaneous adverse reactions following SARS-CoV−2 vaccine booster dose: a real-life multicentre experience’. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18531
210. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. doi:10.1016/j.jaad.2021.03.092
211. Hlaca N, Zagar T, Kastelan M, et al. Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine [published online ahead of print, 2022 Aug 27]. Dermatol Ther. 2022;e15791. doi:10.1111/dth.15791
212. Annabi E, Dupin N, Sohier P, et al. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature. J Eur Acad Dermatol Venereol. 2022;35:e847–e850. doi:10.1111/jdv.17578
213. Hunjan MK, Roberts C, Karim S, et al. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Clin Exp Dermatol. 2022;47:188–190. doi:10.1111/ced.14878
214. Fiorillo G, Pancetti S, Cortese A, et al. Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination. J Autoimmun. 2022;127:102783. doi:10.1016/j.jaut.2021.102783
215. Avalone G, Quaglino P, Cavallo F, et al. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. Int J Dermatol. 2022;61(10):1187–1204. doi:10.1111/ijd.16063
216. Gambichler T, Scheel CH, Arafat Y, et al. Erythodermic pityriasis rubra pilaris after SARS-CoV−2 vaccination with concomitant COVID−19 infection. J Eur Acad Dermatol Venereol. 2022;36:e675–e. doi:10.1111/jdv.18214
217. Nguyễn TH, Gabros S, Friefeld S, et al. Generalized granuloma annulare after COVID-19 vaccination. JAAD Case Rep. 2022;25:18–21. doi:10.1016/j.jdcr.2022.05.003
218. Martora F, Villani A, Battista T, et al. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15414
219. Camela E, Scalvenzi M, Megna M, et al. Reply to “A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination” by Manaia et al. Dermatol Ther. 2022;35(7):e15881.
220. Martora F, Fabbriconi G, Guerriaso G, et al. Reply to ‘A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID−19 vaccine’. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18646
221. Martora F, Fornaro L, Picone V, et al. Herpes zoster and alopecia areata following mRNA BNT162b2 COVID-19 vaccine: controversial immune effects. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15465
222. Martora F, Fabbrocini G, Nappa P, et al. Impact of the COVID−19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
223. Villani A, Potestio L, Fabbrocini G, et al. Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic [published online ahead of print, 2022 Aug 26]. Dermatol Ther. 2022;e15786. doi:10.1111/dth.15786
224. Ruggiero A, Martora F, Fornaro F, et al. Reply to ‘Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier et al. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18512
225. Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1146–1178. doi:10.1002/adv.20444-1
226. Scalvenzi M, Villani A, Mazzella C, et al. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84(6):758–760. doi:10.4103/ijdv.IJDVL_92_18
227. Villani A, Potestio L, Fabbrocini G, et al. The treatment of advanced melanoma: therapeutic update. Int J Mol Sci. 2022;23(12):6388. doi:10.3390/ijms23126388
228. Farr MA, Duvic M, Joshi TP. Teledermatology during COVID-19: an updated review. *Am J Clin Dermatol*. 2021;22(4):467–475. doi:10.1007/s40257-021-00601-y

229. Ruggiero A, Megna M, Fabbrocini G, et al. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. *Clin Exp Dermatol*. 2022. doi:10.1111/ced.15286

230. Megna M, Camela E, Villani A, et al. Teledermatology: a useful tool also after COVID-19 era? *J Cosmet Dermatol*. 2022;21(6):2309–2310. doi:10.1111/jocd.14938

231. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. *Age Ageing*. 2021;50(2):279–283. doi:10.1093/ageing/afaa274

232. Liu Q, Qin C, Liu M, et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. *Infect Dis Poverty*. 2021;10(1):132. doi:10.1186/s40249-021-00915-3

233. Potestio L, Villani A, Fabbrocini G, et al. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? *J Cosmet Dermatol*. 2022. doi:10.1111/jocd.15331